This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Genta Takes Another Stab

But this has been a year in which crazy stuff worked, so we'll know soon enough if Genta can add itself to that list.

My BioBuzz item on Opexa Therapeutics (OPXA - Get Report) perturbed Nicholas, who writes, "Stop hating [Bleep]-hole. You dont [sic] know [Bleep] about Tovaxin or the validity of the data. The data was good. Your [sic] a [Bleeping] political science major, not a medical expert. You dont [sic] know [Bleep] so dont [sic] write 'more of the same' without more evidence and understanding. Your [sic] a loser!!"

I know, Nicholas' spelling needs work, although I'm proud he got "loser" right. (Remember, it's l-o-s-e-r, not l-o-o-s-e-r.)

Judging by his email, I'm not sure I'd want Nicholas to be my go-to expert on Tovaxin either, but his anger was echoed in other emails, all of which accuse me of glossing over the "newness" of Monday's update from the phase II Tovaxin study.

I don't think I did that at all. The point I was making was that Monday's data announcement was "more of the same" about the subgroup of multiple sclerosis patients Opexa cherry-picked out of the failed phase II study from last fall.

I don't see any sensible reason to believe in Tovaxin until the company conducts another randomized and controlled study in these multiple sclerosis patients.

If day traders and momentum investors want to use Opexa as their newest favorite chew toy, then so be it, but please, don't try to base your argument on the strength of the Tovaxin data.
3 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AGEN $3.43 -7.00%
ARNA $1.63 -4.70%
OPXA $2.51 -0.40%
OSIR $5.34 -7.10%
VVUS $1.41 -11.00%


Chart of I:DJI
DOW 17,628.01 -122.90 -0.69%
S&P 500 2,053.90 -9.47 -0.46%
NASDAQ 4,736.2860 -26.9380 -0.57%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs